But Igor, Goldstajn Marina Sprem, Oresković Slavko
University of Maribor, Maribor University Clinical Centre, General Gynaecology and Urogynaecology Department, Gynaecology and Perinatology Clinic, Maribor, Slovenia.
Coll Antropol. 2012 Dec;36(4):1347-53.
Overactive bladder (OAB) is a common, often debilitating, condition defined as urgency and urge incontinence, usually with frequency and nocturia. The use of muscarinic receptor antagonists are the mainstay of treatment, but their non-selectivity can result in unacceptable adverse effects that limit their usefulness. The purpose of this study was to evaluate 2 of the newer antimuscarinic agents, solifenacin and darifenacin, which demonstrate greater selectivity, in order to compare their tolerance and effectiveness. This was a multicentre, prospective, randomised, comparative (1:1) open-label study conducted in 4 centres comprising Slovenian gynaecologists and urologists. A total of 77 female patients with OAB were enrolled who received either solifenacin 5 mg or darifenacin 7.5 mg once daily. Study measurements consisted of changes in OAB symptoms and quality of life (QOL) evaluations after 1 and 3 months of treatment. Both treatment groups showing a reduction in all OAB symptoms but with no notable difference being seen between the 2 groups. Solifenacin though showed statistically greater improvements in QOL, better overall treatment satisfaction, and a decreased incidence of dry mouth after 3 months of treatment compared to the darifenacin group. This study demonstrates interesting initial results and indicates that these 2 drugs have a different profile that may confer an advantage to patients, but further methodologically rigorous studies comparing the use of solifenacin and darifenacin in OAB are required to establish the differences between these drugs over longer periods of treatment.
膀胱过度活动症（OAB）是一种常见且往往使人衰弱的病症，定义为尿急和急迫性尿失禁，通常伴有尿频和夜尿症。使用毒蕈碱受体拮抗剂是主要的治疗方法，但其非选择性可能导致不可接受的不良反应，从而限制了它们的效用。本研究的目的是评估两种新型抗毒蕈碱药物索利那新和达非那新，它们具有更高的选择性，以便比较它们的耐受性和有效性。这是一项在4个中心进行的多中心、前瞻性、随机、对比（1:1）开放标签研究，参与的有斯洛文尼亚的妇科医生和泌尿科医生。共有77名患有OAB的女性患者入组，她们每天接受一次5毫克索利那新或7.5毫克达非那新治疗。研究测量包括治疗1个月和3个月后OAB症状的变化以及生活质量（QOL）评估。两个治疗组的所有OAB症状均有所减轻，但两组之间未观察到显著差异。不过，与达非那新组相比，索利那新在治疗3个月后在生活质量方面有统计学上更大的改善，总体治疗满意度更高，口干发生率降低。这项研究展示了有趣的初步结果，并表明这两种药物具有不同的特点，可能对患者有优势，但需要进一步进行方法学严谨的研究，比较索利那新和达非那新在OAB治疗中的使用情况，以确定这些药物在更长治疗期内的差异。
